Document Detail


Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.
MedLine Citation:
PMID:  21497168     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An outbred rat model of novelty-seeking phenotype has predictive value for the expression of locomotor sensitization to nicotine. When experimentally naïve rats are exposed to a novel environment, some display high rates of locomotor reactivity (HRs, scores ranking at top 1/3rd of the population), whereas some display low rates (LRs, scores ranking at bottom 1/3rd of the population). Basally, HRs display lower anxiety-like behavior compared to LRs along with higher neuropeptide Y (NPY) mRNA in the amygdala and the hippocampus. Following an intermittent behavioral sensitization to nicotine regimen and 1 wk of abstinence, HRs show increased social anxiety-like behavior in the social interaction test and robust expression of locomotor sensitization to a low dose nicotine challenge. These effects are accompanied by a deficit in NPY mRNA levels in the medial nucleus of the amygdala and the CA3 field of the hippocampus, and increases in Y2R mRNA levels in the CA3 field and corticotropin releasing factor (CRF) mRNA levels in the central nucleus of the amygdala. Systemic and daily injections of a Y2R antagonist, JNJ-31020028, during abstinence fully reverse nicotine-induced social anxiety-like behavior, the expression of locomotor sensitization to nicotine challenge, the deficit in the NPY mRNA levels in the amygdala and the hippocampus, as well as result an increase in Y2R mRNA levels in the hippocampus and the CRF mRNA levels in the amygdala in HRs. These findings implicate central Y2R in neuropeptidergic regulation of social anxiety in a behavioral sensitization to nicotine regimen in the LRHR rats.
Authors:
Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Related Documents :
16938038 - The thrill of victory and the agony of defeat: spontaneous expressions of medal winners...
21189258 - Inhibition of proinflammatory rantes expression by tgf-beta1 is mediated by glycogen sy...
21541268 - Patterns of mrna and protein expression during minus-lens compensation and recovery in ...
21292918 - Cyclooxygenase-2 expression is related with localization, proliferation, and overall su...
1614538 - Wild-type p53 activates transcription in vitro.
18221488 - Histone modifications and chromatin dynamics: a focus on filamentous fungi.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-04-08
Journal Detail:
Title:  Behavioural brain research     Volume:  222     ISSN:  1872-7549     ISO Abbreviation:  Behav. Brain Res.     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-05-17     Completed Date:  2011-09-20     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  8004872     Medline TA:  Behav Brain Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  332-41     Citation Subset:  IM    
Copyright Information:
Published by Elsevier B.V.
Affiliation:
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amygdala / drug effects,  metabolism
Animals
Anxiety / blood,  complications,  drug therapy,  metabolism
Benzamides / pharmacology,  therapeutic use*
CA3 Region, Hippocampal / drug effects,  metabolism
Corticosterone / blood
Corticotropin-Releasing Hormone / biosynthesis*
Disease Models, Animal
Exploratory Behavior
Interpersonal Relations
Male
Motor Activity / drug effects
Neuropeptide Y / biosynthesis*
Nicotine / pharmacology*
Phenotype
Piperazines / pharmacology,  therapeutic use*
RNA, Messenger / drug effects*,  metabolism
Rats
Rats, Sprague-Dawley
Receptors, Neuropeptide Y / antagonists & inhibitors*,  biosynthesis,  metabolism,  physiology
Substance Withdrawal Syndrome / complications,  drug therapy*,  metabolism
Grant Support
ID/Acronym/Agency:
DA023675/DA/NIDA NIH HHS; R15 DA023675-01A2/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Benzamides; 0/JNJ-31020028; 0/Neuropeptide Y; 0/Piperazines; 0/RNA, Messenger; 0/Receptors, Neuropeptide Y; 0/neuropeptide Y-Y1 receptor; 0/neuropeptide Y2 receptor; 50-22-6/Corticosterone; 54-11-5/Nicotine; 9015-71-8/Corticotropin-Releasing Hormone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Random insertion of split-cans of the fluorescent protein venus into Shaker channels yields voltage ...
Next Document:  Impairments of exploration and memory after systemic or prelimbic D1-receptor antagonism in rats.